redhill biopharma ltd. - RDHL

RDHL

Close Chg Chg %
1.02 -0.22 -21.56%

Closed Market

0.80

-0.22 (21.56%)

Volume: 5.94M

Last Updated:

Jun 9, 2026, 4:00 PM EDT

Company Overview: redhill biopharma ltd. - RDHL

RDHL Key Data

Open

$0.90

Day Range

0.80 - 0.90

52 Week Range

0.71 - 3.31

Market Cap

$5.30M

Shares Outstanding

5.19M

Public Float

4.62M

Beta

4.97

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$78.99

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

115.89K

 

RDHL Performance

1 Week
 
-0.97%
 
1 Month
 
0.99%
 
3 Months
 
17.24%
 
1 Year
 
-41.71%
 
5 Years
 
-99.99%
 

RDHL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About redhill biopharma ltd. - RDHL

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

RDHL At a Glance

RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv, Tel Aviv 6473921
Phone 972-3-541-3131 Revenue 288.27K
Industry Pharmaceuticals: Major Net Income -432,403.25
Sector Health Technology Employees 13
Fiscal Year-end 12 / 2026
View SEC Filings

RDHL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 11.288
Price to Book Ratio 1.229
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.047
Enterprise Value to Sales 1.225
Total Debt to Enterprise Value 3.031

RDHL Efficiency

Revenue/Employee 22,174.526
Income Per Employee -33,261.788
Receivables Turnover 0.169
Total Asset Turnover 0.013

RDHL Liquidity

Current Ratio 0.34
Quick Ratio 0.34
Cash Ratio 0.207

RDHL Profitability

Gross Margin N/A
Operating Margin -2,765.384
Pretax Margin -2,813.636
Net Margin -150.00
Return on Assets -37.541
Return on Equity N/A
Return on Total Capital -152.571
Return on Invested Capital -3,338.285

RDHL Capital Structure

Total Debt to Total Equity 25.07
Total Debt to Total Capital 20.045
Total Debt to Total Assets 4.222
Long-Term Debt to Equity 21.087
Long-Term Debt to Total Capital 16.86
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Redhill Biopharma Ltd. - RDHL

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
61.56M 6.51M 8.08M 288.27K
Sales Growth
-28.27% -89.42% +24.07% -96.43%
Cost of Goods Sold (COGS) incl D&A
- 33.21M 3.45M 3.21M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
8.12M 1.98M 621.94K 412.24K
Depreciation
2.13M 1.44M 590.79K 387.05K
Amortization of Intangibles
5.99M 543.60K 31.15K 25.20K
COGS Growth
- -32.83% -89.61% -7.04%
Gross Income
- 28.35M 3.06M 4.87M
Gross Income Growth
- -22.06% -89.20% +59.12%
Gross Profit Margin
- +46.06% +47.03% +60.31%
2022 2023 2024 2025 5-year trend
SG&A Expense
71.03M 34.41M 17.19M 7.85M
Research & Development
7.25M 3.52M 1.60M 2.04M
Other SG&A
63.78M 30.90M 15.59M 5.81M
SGA Growth
-39.59% -51.55% -50.06% -54.34%
Other Operating Expense
- - - -
-
Unusual Expense
(13.37M) (21.53M) (4.39M) (1.29M)
EBIT after Unusual Expense
(29.31M) (9.82M) (7.92M) (6.68M)
Non Operating Income/Expense
(41.60M) 34.11M 142.67K (1.08M)
Non-Operating Interest Income
139.45K 93.76K 133.63K 23.18K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
484.10K 426.90K 530.51K 353.78K
Interest Expense Growth
+5.17% -11.82% +24.27% -33.31%
Gross Interest Expense
484.10K 426.90K 530.51K 353.78K
Interest Capitalized
- - - -
-
Pretax Income
(71.39M) 23.85M (8.31M) (8.11M)
Pretax Income Growth
+27.01% +133.41% -134.82% +2.36%
Pretax Margin
-115.97% +366.25% -102.80% -2,813.64%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(71.39M) 23.85M (8.31M) (8.14M)
Minority Interest Expense
- - - -
-
Net Income
(71.39M) 23.85M (8.31M) (8.14M)
Net Income Growth
+27.01% +133.41% -134.82% +1.96%
Net Margin Growth
-115.97% +366.25% -102.80% -2,825.17%
Extraordinaries & Discontinued Operations
- - - 7.71M
-
Discontinued Operations
- - - 7.71M
-
Net Income After Extraordinaries
(71.39M) 23.85M (8.31M) (432.40K)
Preferred Dividends
- - - -
-
Net Income Available to Common
(71.39M) 23.85M (8.31M) (432.40K)
EPS (Basic)
-1152.7718 92.0622 -6.7318 -0.1008
EPS (Basic) Growth
+45.16% +107.99% -107.31% +98.50%
Basic Shares Outstanding
61.93K 259.12K 1.23M 3.16M
EPS (Diluted)
-1152.7718 92.0622 -6.7318 -0.1008
EPS (Diluted) Growth
+45.16% +107.99% -107.31% +98.50%
Diluted Shares Outstanding
61.93K 259.12K 1.23M 3.16M
EBITDA
(34.55M) (29.37M) (11.69M) (7.56M)
EBITDA Growth
+45.18% +15.01% +60.19% +35.33%
EBITDA Margin
-56.13% -450.87% -144.66% -2,622.38%

Redhill Biopharma Ltd. in the News